GSK shelved its chronic cough bet camlipixant after mixed Phase 3 results in refractory chronic cough, according to company-linked reporting. Calm-1 met its primary endpoint at week 12 with cough frequency reductions versus placebo, but Calm-2 missed key thresholds at week 24 and the 25 mg regimen did not perform. The discontinuation ends momentum behind a program acquired via GSK’s Bellus Health deal and reshuffles competitive positioning for chronic cough, where Trevi Therapeutics’ alternative asset Haduvio is highlighted as benefiting from the space opening. The outcome further illustrates how late-stage efficacy volatility can rapidly change resource allocation.